person · Reporting owner

VAN NOSTRAND ROBERT L

Disclosed activity across 5 companies

Tapewire entity: 69643
SEC CIK: 0001225198

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Enumeral Biomedical Holdings, Inc.ENUM · Entity 179878	Director	January 03, 2017	January 05, 2017
SELLAS Life Sciences Group, Inc.SLS · Entity 4313	Director	January 07, 2026	January 09, 2026
YIELD10 BIOSCIENCE, INC.YTEN · Entity 88195	Director	March 28, 2024	April 01, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Enumeral Biomedical Holdings, Inc.

Report date January 03, 2017 · Filed January 05, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	268,121	Reported balance After 2017-01-03 transaction · row 1 1 source row Row 1 · 2017-01-03 · Grant · Acquired 66,666 · Balance 268,121 F1: Represents a restricted stock award granted by Enumeral Biomedical Holdings, Inc. (the "Company") pursuant to its non-employee director compensation program and the Company's 2014 Equity Incentive Plan, as amended. The restrictions on the shares underlying this award lapse in 4 quarterly installments on each of January 3, 2017, April 1, 2017, July 1, 2017, and October 1, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock award granted by Enumeral Biomedical Holdings, Inc. (the "Company") pursuant to its non-employee director compensation program and the Company's 2014 Equity Incentive Plan, as amended. The restrictions on the shares underlying this award lapse in 4 quarterly installments on each of January 3, 2017, April 1, 2017, July 1, 2017, and October 1, 2017.

SELLAS Life Sciences Group, Inc.

Report date January 07, 2026 · Filed January 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	82,900	Reported balance After 2026-01-07 transaction · row 1 1 source row Row 1 · 2026-01-07 · Grant · Acquired 50,000 · Balance 82,900 F1: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

YIELD10 BIOSCIENCE, INC.

Report date March 28, 2024 · Filed April 01, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	48,635	Reported balance After 2024-03-28 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-03-28 · Grant · Acquired 11,924 · Balance 48,635 F1: Shares were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Shares were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2024.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACHILLION PHARMACEUTICALS INC

Report date January 28, 2020 · Filed January 29, 2020

Section 16 reporting ended · disclosed 2020-01-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-01-28 transaction · row 1 1 source row Row 1 · 2020-01-28 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.59 · Expires 2021-12-12	Direct	Reported balance After 2020-01-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-28 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.54 · Expires 2026-01-25	Direct	Reported balance After 2020-01-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2027-01-19	Direct	Reported balance After 2020-01-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.10 · Expires 2020-12-16	Direct	Reported balance After 2020-01-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-01-28 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.02 · Expires 2023-12-17	Direct	Reported balance After 2020-01-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-01-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2028-02-09	Direct	Reported balance After 2020-01-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2029-01-23	Direct	Reported balance After 2020-01-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-01-28 · Disposition to issuer · Disposed 42,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.

F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.

Intra-Cellular Therapies, Inc.

Report date April 02, 2025 · Filed April 02, 2025

Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-04-02 transaction · row 1 1 source row Row 1 · 2025-04-02 · Disposition to issuer · Disposed 11,340 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.58 · Expires 2025-06-15	Direct	Reported balance After 2025-04-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.35 · Expires 2026-06-13	Direct	Reported balance After 2025-04-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.39 · Expires 2028-06-17	Direct	Reported balance After 2025-04-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.02 · Expires 2030-05-26	Direct	Reported balance After 2025-04-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.45 · Expires 2031-06-20	Direct	Reported balance After 2025-04-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.48 · Expires 2032-06-08	Direct	Reported balance After 2025-04-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-04-02 · Disposition to issuer · Disposed 16,757 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.79 · Expires 2033-06-22	Direct	Reported balance After 2025-04-02 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-04-02 · Disposition to issuer · Disposed 7,009 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.77 · Expires 2034-06-13	Direct	Reported balance After 2025-04-02 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-04-02 · Disposition to issuer · Disposed 4,322 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2025-04-02 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-04-02 · Disposition to issuer · Disposed 2,951 · Balance 0 F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share. F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F7: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").

F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.

F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share.

F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.

F7: Not applicable.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 28, 2019 Filed Jul 2, 2019 09:47 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	5,096	$0.89 Strike: $0.97	$4,535.44	Disclosure SEC source: 0001179110-19-008278 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,096 Underlying: Common Stock · 5,096 shares Expires 2029-06-28 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the second quarter of 2019. Read SEC document
June 28, 2019 Filed Jul 2, 2019 17:17 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	449	$12.98	$5,828.02	Disclosure SEC source: 0001209191-19-040463 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,882 Read SEC document
June 25, 2019 Filed Jun 26, 2019 16:45 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001209191-19-039116 · doc4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-24 Read SEC document
May 22, 2019 Filed May 23, 2019 16:33 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $0.90	$0.00	Disclosure SEC source: 0001179110-19-006582 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-22 F1 · shares: These options were issued to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors and/or a committee thereof. F2 · derivative.exercise_date: These options will vest and become exercisable in equal quarterly installments over 4 years from 5/22/19, beginning on 8/22/2019 and ending on 5/22/2023. Read SEC document
March 31, 2019 Filed Apr 2, 2019 18:59 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	478	$12.18	$5,822.04	Disclosure SEC source: 0001209191-19-022725 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,433 Read SEC document
March 29, 2019 Filed Apr 2, 2019 11:25 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	4,321	$1.05 Strike: $1.14	$4,537.05	Disclosure SEC source: 0001179110-19-004443 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,321 Underlying: Common Stock · 4,321 shares Expires 2029-03-29 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2019. Read SEC document
March 14, 2019 Filed Mar 18, 2019 19:03 UTC	SELLAS Life Sciences Group, Inc. SLS · Entity 4313	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $1.38	$0.00	Disclosure SEC source: 0000899243-19-008205 · doc4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-03-14 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) March 14, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document
January 23, 2019 Filed Jan 25, 2019 16:55 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	GrantStock Option (Right to buy) · Derivative	42,000	$0.00 Strike: $2.18	$0.00	Disclosure SEC source: 0001209191-19-005381 · doc4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: This option vests and becomes exercisable in equal quarterly installments over the one-year period following the date of grant. Read SEC document
December 31, 2018 Filed Jan 3, 2019 13:45 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	5,924	$0.76 Strike: $0.83	$4,502.24	Disclosure SEC source: 0001179110-19-000160 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,924 Underlying: Common Stock · 5,924 shares Expires 2028-12-31 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the fourth quarter of 2018. Read SEC document
December 31, 2018 Filed Jan 3, 2019 20:19 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	512	$11.39	$5,831.68	Disclosure SEC source: 0001209191-19-001553 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,955 Read SEC document
December 14, 2018 Filed Dec 18, 2018 16:22 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Exercise / conversionEmployee Stock Option · Derivative	20,000	$0.00 Strike: $1.05	$0.00	Disclosure SEC source: 0001209191-18-063170 · doc4.xml · derivative · entry 2 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2018-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on December 15, 2008 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter. Read SEC document
December 14, 2018 Filed Dec 18, 2018 16:22 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Exercise / conversionCommon Stock	20,000	$1.05	$21,000.00	Disclosure SEC source: 0001209191-18-063170 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 30, 2018 Filed Oct 2, 2018 20:06 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	268	$21.70	$5,815.60	Disclosure SEC source: 0001209191-18-053526 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,443 Read SEC document
September 28, 2018 Filed Oct 2, 2018 11:37 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	3,396	$1.33 Strike: $1.44	$4,516.68	Disclosure SEC source: 0001179110-18-011807 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,396 Underlying: Common Stock · 3,396 shares Expires 2028-09-28 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the third quarter of 2018. Read SEC document
June 29, 2018 Filed Jul 3, 2018 15:08 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	3,464	$1.31 Strike: $1.41	$4,537.84	Disclosure SEC source: 0001179110-18-009303 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,464 Underlying: Common Stock · 3,464 shares Expires 2028-06-29 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the second quarter of 2018. Read SEC document
June 29, 2018 Filed Jul 3, 2018 16:22 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	282	$17.67	$4,982.94	Disclosure SEC source: 0001209191-18-041056 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,175 Read SEC document
June 18, 2018 Filed Jun 20, 2018 16:47 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $20.39	$0.00	Disclosure SEC source: 0001209191-18-038790 · doc4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-17 Read SEC document
June 12, 2018 Filed Jun 13, 2018 18:32 UTC	SELLAS Life Sciences Group, Inc. SLS · Entity 4313	GrantStock Option (Right to Buy) · Derivative	5,500	$0.00 Strike: $5.23	$0.00	Disclosure SEC source: 0001209191-18-037553 · doc4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2028-06-11 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) June 12, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document
May 23, 2018 Filed May 25, 2018 10:56 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $1.65	$0.00	Disclosure SEC source: 0001179110-18-007511 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-23 F1 · shares: These options were issued to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors and/or a committee thereof. F2 · derivative.exercise_date: These options will vest and become exercisable in equal quarterly installments over 4 years from 5/23/18, beginning on 8/23/2018 and ending on 5/23/2022. Read SEC document
March 30, 2018 Filed Apr 3, 2018 16:19 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	237	$21.05	$4,988.85	Disclosure SEC source: 0001209191-18-022932 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,893 Read SEC document
March 29, 2018 Filed Apr 2, 2018 17:29 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	2,860	$1.58 Strike: $1.95	$4,518.80	Disclosure SEC source: 0001179110-18-005075 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,860 Underlying: Common Stock · 2,860 shares Expires 2028-03-29 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2018. Read SEC document
March 13, 2018 Filed Mar 15, 2018 20:01 UTC	SELLAS Life Sciences Group, Inc. SLS · Entity 4313	GrantStock Option (Right to Buy) · Derivative	11,000	$0.00 Strike: $5.24	$0.00	Disclosure SEC source: 0001209191-18-020019 · doc4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: The option shares will vest and became exercisable in equal monthly installments for thirty-six (36) months following the March 13, 2018 grant date, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document
February 09, 2018 Filed Feb 13, 2018 17:13 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	GrantEmployee Stock Option · Derivative	30,000	$0.00 Strike: $2.90	$0.00	Disclosure SEC source: 0001209191-18-009654 · doc4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-02-09 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the date of grant and as to an additional 2.08% of the original number of shares at the end of each monthly period thereafter. Read SEC document
December 29, 2017 Filed Jan 3, 2018 16:53 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	13,003	$1.39 Strike: $1.77	$18,074.17	Disclosure SEC source: 0001179110-18-000317 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,003 Underlying: Common Stock · 13,003 shares Expires 2027-12-29 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $18,125 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the fourth quarter of 2017. Read SEC document
December 29, 2017 Filed Jan 3, 2018 18:10 UTC Amendment	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	345	$14.48	$4,995.60	Disclosure SEC source: 0001209191-18-001234 · doc4a.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,656 Read SEC document
December 29, 2017 Filed Jan 3, 2018 16:31 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	PurchaseCommon Stock	345	$14.48	$4,995.60	Disclosure SEC source: 0001209191-18-000898 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,656 Read SEC document
November 28, 2017 Filed Nov 30, 2017 16:20 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	10,165	$0.00 Strike: $2.34	$0.00	Disclosure SEC source: 0001179110-17-014726 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,165 Underlying: Common Stock · 10,165 shares Expires 2027-11-28 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the third quarter of 2017. F2 · balance_after: All share numbers reported reflect the 1-for-10 reverse stock split effected on May 30, 2017. Read SEC document
September 29, 2017 Filed Oct 3, 2017 18:19 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	316	$0.00	$0.00	Disclosure SEC source: 0001209191-17-055393 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,311 Read SEC document
June 30, 2017 Filed Jul 5, 2017 16:19 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantCommon Stock	3,519	$0.00	$0.00	Disclosure SEC source: 0001179110-17-009984 · edgar.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,293 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the second quarter of 2017. F2 · balance_after: All share numbers reported reflect the 1-for-10 reverse stock split effected on May 30, 2017. Read SEC document
June 30, 2017 Filed Jul 5, 2017 18:07 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	402	$0.00	$0.00	Disclosure SEC source: 0001209191-17-043583 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,995 Read SEC document
June 27, 2017 Filed Jun 29, 2017 16:26 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $12.45	$0.00	Disclosure SEC source: 0001209191-17-042299 · doc4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-27 Read SEC document
May 24, 2017 Filed May 26, 2017 16:07 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $0.42	$0.00	Disclosure SEC source: 0001179110-17-008074 · edgar.xml · derivative · entry 2 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-24 F2 · shares: These options were issued to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors and/or a committee thereof. Read SEC document
May 24, 2017 Filed May 26, 2017 16:07 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantCommon Stock	43,155	$0.00	$0.00	Disclosure SEC source: 0001179110-17-008074 · edgar.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,488 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2017. Read SEC document
March 31, 2017 Filed Apr 4, 2017 17:02 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	307	$0.00	$0.00	Disclosure SEC source: 0001209191-17-025012 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,593 Read SEC document
January 19, 2017 Filed Jan 19, 2017 17:28 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	GrantEmployee Stock Option · Derivative	30,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001209191-17-004621 · doc4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-19 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the date of grant and as to an additional 2.08% of the original number of shares at the end of each monthly period thereafter. Read SEC document
January 03, 2017 Filed Jan 5, 2017 16:20 UTC	Enumeral Biomedical Holdings, Inc. ENUM · Entity 179878	GrantCommon Stock	66,666	$0.00	$0.00	Disclosure SEC source: 0001615774-17-000042 · s105079_form4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,121 F1 · shares: Represents a restricted stock award granted by Enumeral Biomedical Holdings, Inc. (the "Company") pursuant to its non-employee director compensation program and the Company's 2014 Equity Incentive Plan, as amended. The restrictions on the shares underlying this award lapse in 4 quarterly installments on each of January 3, 2017, April 1, 2017, July 1, 2017, and October 1, 2017. Read SEC document
December 30, 2016 Filed Jan 3, 2017 16:33 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	331	$0.00	$0.00	Disclosure SEC source: 0001209191-17-000258 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,286 Read SEC document
December 09, 2016 Filed Dec 13, 2016 17:31 UTC	Enumeral Biomedical Holdings, Inc. ENUM · Entity 179878	Exercise / conversionCommon Stock Purchase Warrant · Derivative	156,000	$0.13 Strike: $0.50	$19,500.00	Disclosure SEC source: 0001615774-16-008880 · s104936_form4.xml · derivative · entry 4 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 156,000 shares Expires 2016-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Pursuant to an Offer to Amend and Exercise launched by the Issuer on October 28, 2016 (as subsequently amended, the "Offering"), the exercise price of each Warrant tendered in the Offering was reduced to $0.50 per Warrant, and participants in the Offering received four shares for each Warrant tendered rather than one share. Pursuant to the terms of the Offering, the expiration date of tendered Warrants was accelerated to December 9, 2016. The Reporting Person tendered all of the Warrants beneficially owned in the Offering. F3 · price: Pursuant to an Offer to Amend and Exercise launched by the Issuer on October 28, 2016 (as subsequently amended, the "Offering"), the exercise price of each Warrant tendered in the Offering was reduced to $0.50 per Warrant, and participants in the Offering received four shares for each Warrant tendered rather than one share. Pursuant to the terms of the Offering, the expiration date of tendered Warrants was accelerated to December 9, 2016. The Reporting Person tendered all of the Warrants beneficially owned in the Offering. F1 · derivative.exercise_date: The Common Stock Purchase Warrants (the "Warrants") are exercisable immediately. F3 · derivative.expiration_date: Pursuant to an Offer to Amend and Exercise launched by the Issuer on October 28, 2016 (as subsequently amended, the "Offering"), the exercise price of each Warrant tendered in the Offering was reduced to $0.50 per Warrant, and participants in the Offering received four shares for each Warrant tendered rather than one share. Pursuant to the terms of the Offering, the expiration date of tendered Warrants was accelerated to December 9, 2016. The Reporting Person tendered all of the Warrants beneficially owned in the Offering. Read SEC document
December 09, 2016 Filed Dec 13, 2016 17:31 UTC	Enumeral Biomedical Holdings, Inc. ENUM · Entity 179878	OtherCommon Stock Purchase Warrant · Derivative	156,000	$0.13 Strike: $0.50	$19,500.00	Disclosure SEC source: 0001615774-16-008880 · s104936_form4.xml · derivative · entry 3 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,000 Underlying: Common Stock · 156,000 shares Expires 2016-12-09 F3 · derivative.exercise_price: Pursuant to an Offer to Amend and Exercise launched by the Issuer on October 28, 2016 (as subsequently amended, the "Offering"), the exercise price of each Warrant tendered in the Offering was reduced to $0.50 per Warrant, and participants in the Offering received four shares for each Warrant tendered rather than one share. Pursuant to the terms of the Offering, the expiration date of tendered Warrants was accelerated to December 9, 2016. The Reporting Person tendered all of the Warrants beneficially owned in the Offering. F3 · price: Pursuant to an Offer to Amend and Exercise launched by the Issuer on October 28, 2016 (as subsequently amended, the "Offering"), the exercise price of each Warrant tendered in the Offering was reduced to $0.50 per Warrant, and participants in the Offering received four shares for each Warrant tendered rather than one share. Pursuant to the terms of the Offering, the expiration date of tendered Warrants was accelerated to December 9, 2016. The Reporting Person tendered all of the Warrants beneficially owned in the Offering. F1 · derivative.exercise_date: The Common Stock Purchase Warrants (the "Warrants") are exercisable immediately. F3 · derivative.expiration_date: Pursuant to an Offer to Amend and Exercise launched by the Issuer on October 28, 2016 (as subsequently amended, the "Offering"), the exercise price of each Warrant tendered in the Offering was reduced to $0.50 per Warrant, and participants in the Offering received four shares for each Warrant tendered rather than one share. Pursuant to the terms of the Offering, the expiration date of tendered Warrants was accelerated to December 9, 2016. The Reporting Person tendered all of the Warrants beneficially owned in the Offering. Read SEC document
December 09, 2016 Filed Dec 13, 2016 17:31 UTC	Enumeral Biomedical Holdings, Inc. ENUM · Entity 179878	PurchaseCommon Stock Purchase Warrant · Derivative	39,000	$0.08 Strike: $2.00	$3,120.00	Disclosure SEC source: 0001615774-16-008880 · s104936_form4.xml · derivative · entry 2 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 39,000 shares Expires 2019-07-30 F2 · price: The Reporting Person acquired the reported Warrants in a private sale transaction for cash consideration in the amount of $0.08 per warrant. F1 · derivative.exercise_date: The Common Stock Purchase Warrants (the "Warrants") are exercisable immediately. Read SEC document
December 09, 2016 Filed Dec 13, 2016 17:31 UTC	Enumeral Biomedical Holdings, Inc. ENUM · Entity 179878	Exercise / conversionCommon Stock	156,000	$0.13	$19,500.00	Disclosure SEC source: 0001615774-16-008880 · s104936_form4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 30, 2016 Filed Oct 4, 2016 16:45 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	328	$0.00	$0.00	Disclosure SEC source: 0001209191-16-144341 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,955 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.